十六烷基磷酸胆碱（米替福新）、两性霉素B脂质体和葡萄糖酸锑钠（喷他脒）对免疫缺陷型重度联合免疫缺陷（scid）小鼠体内杜氏利什曼原虫的活性。
Activities of hexadecylphosphocholine (miltefosine), AmBisome, and sodium stibogluconate (Pentostam) against Leishmania donovani in immunodeficient scid mice.
作者信息
Escobar P, Yardley V, Croft S L
机构信息
Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London WC1E 7HT, United Kingdom.
出版信息
Antimicrob Agents Chemother. 2001 Jun;45(6):1872-5. doi: 10.1128/AAC.45.6.1872-1875.2001.
Abstract
In both scid and BALB/c mouse-Leishmania donovani models, hexadecyphosphocholine (miltefosine) and AmBisome had similar levels of activity. In contrast, sodium stibogluconate (Pentostam) was significantly less active against L. donovani in scid mice than in BALB/c mice. The in vitro anti-leishmanial activity of miltefosine was similar in peritoneal macrophages derived from both scid and BALB/c mice, whereas Pentostam and AmBisome were significantly more active in the latter.
摘要
在严重联合免疫缺陷（scid）小鼠和BALB/c小鼠利什曼原虫（杜氏利什曼原虫）模型中，十六烷基磷胆碱（米替福新）和两性霉素B脂质体具有相似的活性水平。相比之下，葡糖酸锑钠（喷他脒）对scid小鼠体内的杜氏利什曼原虫的活性明显低于对BALB/c小鼠体内该寄生虫的活性。米替福新对源自scid小鼠和BALB/c小鼠的腹腔巨噬细胞的体外抗利什曼原虫活性相似，而喷他脒和两性霉素B脂质体对后者的活性明显更高。
相似文献
1
Activities of hexadecylphosphocholine (miltefosine), AmBisome, and sodium stibogluconate (Pentostam) against Leishmania donovani in immunodeficient scid mice.
Antimicrob Agents Chemother. 2001 Jun;45(6):1872-5. doi: 10.1128/AAC.45.6.1872-1875.2001.
2
In vitro susceptibility of field isolates of Leishmania donovani to Miltefosine and amphotericin B: correlation with sodium antimony gluconate susceptibility and implications for treatment in areas of endemicity.
Antimicrob Agents Chemother. 2009 Feb;53(2):835-8. doi: 10.1128/AAC.01233-08. Epub 2008 Nov 17.
3
In vitro and in vivo interactions between miltefosine and other antileishmanial drugs.
Antimicrob Agents Chemother. 2006 Jan;50(1):73-9. doi: 10.1128/AAC.50.1.73-79.2006.
4
Leishmania donovani: an in vitro study of antimony-resistant amphotericin B-sensitive isolates.
Exp Parasitol. 2006 Dec;114(4):247-52. doi: 10.1016/j.exppara.2006.03.016. Epub 2006 May 23.
5
In vivo and in vitro antileishmanial activity of Bungarus caeruleus snake venom through alteration of immunomodulatory activity.
Exp Parasitol. 2013 Sep;135(1):126-33. doi: 10.1016/j.exppara.2013.06.006. Epub 2013 Jul 3.
6
Amphotericin B inhibits entry of Leishmania donovani into primary macrophages.
Biochem Biophys Res Commun. 2010 Aug 27;399(3):429-33. doi: 10.1016/j.bbrc.2010.07.099. Epub 2010 Aug 3.
7
Magnitude of unresponsiveness to sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar.
Natl Med J India. 2005 May-Jun;18(3):131-3.
8
[A case of antimony resistant kala-azar cured with amphotericin B].
Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi. 2007 Jun;25(3):inside front page.
9
In vitro interactions between sitamaquine and amphotericin B, sodium stibogluconate, miltefosine, paromomycin and pentamidine against Leishmania donovani.
J Antimicrob Chemother. 2011 Apr;66(4):850-4. doi: 10.1093/jac/dkq542. Epub 2011 Feb 3.
10
Refractoriness to the treatment of sodium stibogluconate in Indian kala-azar field isolates persist in in vitro and in vivo experimental models.
Parasitol Res. 2005 Jun;96(4):216-23. doi: 10.1007/s00436-005-1339-1. Epub 2005 May 3.
引用本文的文献
1
Protective Efficacy in a Hamster Model of a Multivalent Vaccine for Human Visceral Leishmaniasis (MuLeVaClin) Consisting of the KMP11, LEISH-F3+, and LJL143 Antigens in Virosomes, Plus GLA-SE Adjuvant.
Microorganisms. 2021 Oct 29;9(11):2253. doi: 10.3390/microorganisms9112253.
2
Oral treatment with T6-loaded yeast cell wall particles reduces the parasitemia in murine visceral leishmaniasis model.
Sci Rep. 2019 Dec 27;9(1):20080. doi: 10.1038/s41598-019-56647-w.
3
Preclinical candidate for the treatment of visceral leishmaniasis that acts through proteasome inhibition.
Proc Natl Acad Sci U S A. 2019 May 7;116(19):9318-9323. doi: 10.1073/pnas.1820175116. Epub 2019 Apr 8.
4
A chronic bioluminescent model of experimental visceral leishmaniasis for accelerating drug discovery.
PLoS Negl Trop Dis. 2019 Feb 14;13(2):e0007133. doi: 10.1371/journal.pntd.0007133. eCollection 2019 Feb.
5
Identification of GSK3186899/DDD853651 as a Preclinical Development Candidate for the Treatment of Visceral Leishmaniasis.
J Med Chem. 2019 Feb 14;62(3):1180-1202. doi: 10.1021/acs.jmedchem.8b01218. Epub 2018 Dec 20.
6
Cyclin-dependent kinase 12 is a drug target for visceral leishmaniasis.
Nature. 2018 Aug;560(7717):192-197. doi: 10.1038/s41586-018-0356-z. Epub 2018 Jul 25.
7
Is Visceral Leishmaniasis the same in HIV-coinfected adults?
Braz J Infect Dis. 2018 Mar-Apr;22(2):92-98. doi: 10.1016/j.bjid.2018.03.001. Epub 2018 Mar 27.
8
Use of Optical Imaging Technology in the Validation of a New, Rapid, Cost-Effective Drug Screen as Part of a Tiered Screening Paradigm for Development of Drugs To Treat Cutaneous Leishmaniasis.
Antimicrob Agents Chemother. 2017 Mar 24;61(4). doi: 10.1128/AAC.02048-16. Print 2017 Apr.
9
Ex vivo host and parasite response to antileishmanial drugs and immunomodulators.
PLoS Negl Trop Dis. 2015 May 29;9(5):e0003820. doi: 10.1371/journal.pntd.0003820. eCollection 2015 May.
10
Nanomedicines in gastroenterology and hepatology.
Nat Rev Gastroenterol Hepatol. 2015 Apr;12(4):195-204. doi: 10.1038/nrgastro.2015.37. Epub 2015 Mar 10.
本文引用的文献
1
Interleukin-12 regulates the response to chemotherapy in experimental visceral Leishmaniasis.
J Infect Dis. 2000 Nov;182(5):1497-502. doi: 10.1086/315890. Epub 2000 Oct 9.
2
Liposomal amphotericin B and amphotericin B-deoxycholate show different immunoregulatory effects on human peripheral blood mononuclear cells.
J Infect Dis. 2000 Jun;181(6):2003-10. doi: 10.1086/315517. Epub 2000 Jun 5.
3
A comparison of the activities of three amphotericin B lipid formulations against experimental visceral and cutaneous leishmaniasis.
Int J Antimicrob Agents. 2000 Feb;13(4):243-8. doi: 10.1016/s0924-8579(99)00133-8.
4
Visceral leishmanicidal activity of hexadecylphosphocholine (miltefosine) in mice deficient in T cells and activated macrophage microbicidal mechanisms.
J Infect Dis. 2000 Feb;181(2):795-9. doi: 10.1086/315268.
5
Visceral leishmaniasis in clinical practice.
J Infect. 1999 Sep;39(2):112-6. doi: 10.1016/s0163-4453(99)90001-4.
6
Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis.
N Engl J Med. 1999 Dec 9;341(24):1795-800. doi: 10.1056/NEJM199912093412403.
7
Topical treatment with hexadecylphosphocholine (Miltex) efficiently reduces parasite burden in experimental cutaneous leishmaniasis.
Trans R Soc Trop Med Hyg. 1999 Jan-Feb;93(1):85-90. doi: 10.1016/s0035-9203(99)90192-x.
8
Global control and Leishmania HIV co-infection.
Clin Dermatol. 1999 May-Jun;17(3):317-25. doi: 10.1016/s0738-081x(99)00050-4.
9
Trial of oral miltefosine for visceral leishmaniasis.
Lancet. 1998 Dec 5;352(9143):1821-3. doi: 10.1016/S0140-6736(98)04367-0.
10
Do the diminishing efficacy and increasing toxicity of sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar, India, justify its continued use as a first-line drug? An observational study of 80 cases.
Ann Trop Med Parasitol. 1998 Jul;92(5):561-9. doi: 10.1080/00034989859258.
Zotero 插件